BAsel Syncope EvaLuation (BASEL IX) Study
Key facts
- Who runs it
- University Hospital, Basel, Switzerland
- Where
- Houston, United StatesSee the siteAlso in 8 other countries, 14 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 3,500 people, planned
- Started
- Apr 2010
- Ended
- Dec 2025
- Type of study
- Observational
- Record updated
- 15 April 2025
Who can take part
- Age
- 40 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Patients presenting to the emergency department
- Age > 40 years
- Syncope within the last 12 hours
- Written informed consent
Who cannot take part
- Patients without loss of consciousness and with certain neurological causes (e.g. recurrent epilepsy, hemiplegia at presentation)
- Age < 40 years
- No written informed consent
Where in United States
Also in 8 other countries, 14 sites
- Baylor College of MedicineHouston, United States
About the trial
What the trial wants to find out
Syncope is a major health problem. In the emergency department (ED), the management of patients with syncope still remains a clinical challenge because underlying diseases and prognosis can be extremely various. Structural heart disease and primary electrical disorders are major risk factors for sudden cardiac death and mortality in patients with syncope. In contrast, patients with reflex syncope and exclusion of structural heart disease have an excellent prognosis.
Read full original descriptionShow less
Therefore The investigators test the hypothesis that the use of a meticulous patient history, clinical examination and novel biomarkers can improve the rapid and accurate diagnosis of cardiac syncope in patients presenting to the ED and is able to improve risk stratification regarding adverse outcomes.
The prospective multicenter cohort study is designed to enroll 720 patients presenting with transient loss of consciousness within the last 12 hours to the ED. Blood samples for the measurement of novel biomarkers will be obtained at presentation.
All patients will be contacted by phone at 6, 12 and 24 months to determine major adverse events (death, resuscitation, recurrence of syncope, hospitalization for syncope).
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Development of an electrocardiogram-based risk calculator for a cardiac cause of syncope.Heart (British Cardiac Society), 2021
- Prevalence of Pulmonary Embolism in Patients With Syncope.Journal of the American College of Cardiology, 2019
- B-Type Natriuretic Peptides and Cardiac Troponins for Diagnosis and Risk-Stratification of Syncope.Circulation, 2019
- Record updated
- 15 April 2025